Replay available

Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call

Harvard Bioscience, Inc. (NASDAQ: HBIO) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.

Thu, November 6, 2025 at 8:00 AMendedReplay
Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call

Investor webinar replay

Latest news releases

Companies on this event

Featured Presenters

Taylor Krafcik

Senior Vice President, Ellipsis TA

John Duke

President and Chief Executive Officer

Mark Frost

Interim Chief Financial Officer

Lucas Baranowski

Analyst, KeyBank Capital Markets

Bruce Jackson

Analyst, The Benchmark Company

Replay transcript excerpt

Good day, and welcome to the third quarter 2025 Harvard Bioscience Earnings Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, please press star 1-1. If your question hasn't answered and you would like to remove yourself from the queue, please press star 1-1 again. Please note, this event is being recorded. I'd like to turn the conference over to Taylor Krafcik, Senior Vice President at Ellipsis TA. Please go ahead. Thank you, Operator, and good morning, everyone. Thank you for joining the Harvard Bioscience third quarter 2025 earnings conference call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer. In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks that is posted to the investor relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management's expectations of future events, or future financial performance are forward-looking statements and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience's management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Forum 10Q, and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and t...

More from Harvard Bioscience, Inc.